Limb-girdle muscular dystrophy
MONDO:0016971Limb-girdle muscular dystrophy (LGMD) is a heterogeneous group of muscular dystrophies characterized by proximal weakness affecting the pelvic and shoulder girdles. Cardiac and respiratory impairment may be observed in certain forms of LGMD.
Also known as: LGMD, Leyden-Mobius muscular dystrophy, limb-girdle muscular dystrophy
31 clinical trials for this condition and its sub-types, 17 tagged with Limb-girdle muscular dystrophy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Limb-girdle muscular dystrophy
-
Autosomal recessive limb-girdle muscular dystrophy 0 trials · 18 incl. sub-types
32 sub-types
- Autosomal recessive limb-girdle muscular dystrophy type 2I 8 trials
- Autosomal recessive limb-girdle muscular dystrophy type 2A 5 trials
- Autosomal recessive limb-girdle muscular dystrophy type 2E 5 trials
- Autosomal recessive limb-girdle muscular dystrophy type 2C 4 trials
- Autosomal recessive limb-girdle muscular dystrophy type 2B 3 trials
- Autosomal recessive limb-girdle muscular dystrophy type 2D 3 trials
- Autosomal recessive limb-girdle muscular dystrophy type 2F 2 trials
- Autosomal recessive limb-girdle muscular dystrophy type 2L 2 trials
- Autosomal recessive limb-girdle muscular dystrophy type 2G 1 trial
- Autosomal recessive limb-girdle muscular dystrophy type 2J 1 trial
- Autosomal recessive limb-girdle muscular dystrophy type 2K 1 trial
- Autosomal recessive limb-girdle muscular dystrophy type 2M 1 trial
- Autosomal recessive limb-girdle muscular dystrophy type 2N 1 trial
- Autosomal recessive limb-girdle muscular dystrophy type 2O 1 trial
- Autosomal recessive limb-girdle muscular dystrophy type 2P 1 trial
- Autosomal recessive limb-girdle muscular dystrophy type 2Q 1 trial
- Autosomal recessive limb-girdle muscular dystrophy type 2R1 1 trial
- Autosomal recessive limb-girdle muscular dystrophy type 2T 1 trial
- Autosomal recessive limb-girdle muscular dystrophy type 2U 1 trial
- Autosomal recessive limb-girdle muscular dystrophy type 2W 1 trial
- Autosomal recessive limb-girdle muscular dystrophy type 2X 1 trial
- Autosomal recessive limb-girdle muscular dystrophy type 2Y 1 trial
- Autosomal recessive limb-girdle muscular dystrophy type R18 1 trial
- Autosomal recessive limb-girdle muscular dystrophy type 2H 0 trials
- Epidermolysis bullosa simplex 5B, with muscular dystrophy 0 trials
- Limb-girdle muscular dystrophy due to POMK deficiency 0 trials
- Muscular dystrophy, limb-girdle, autosomal recessive 23 0 trials
- Muscular dystrophy, limb-girdle, autosomal recessive 26 0 trials
- Muscular dystrophy, limb-girdle, autosomal recessive 27 0 trials
- Muscular dystrophy, limb-girdle, autosomal recessive 28 0 trials
- Muscular dystrophy, limb-girdle, autosomal recessive 29 0 trials
- Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 8 0 trials
-
Muscular dystrophy, limb-girdle, autosomal dominant 0 trials · 4 incl. sub-types
8 sub-types
- Emery-Dreifuss muscular dystrophy 2, autosomal dominant 3 trials
- Autosomal dominant limb-girdle muscular dystrophy type 1D (DNAJB6) 2 trials
- Autosomal dominant limb-girdle muscular dystrophy type 1F 1 trial
- Autosomal dominant limb-girdle muscular dystrophy type 1G 1 trial
- Autosomal dominant limb-girdle muscular dystrophy type 1H 1 trial
- Autosomal dominant limb-girdle muscular dystrophy type 1E (DES) 0 trials
- Muscular dystrophy, limb-girdle, autosomal dominant 4 0 trials
- Myofibrillar myopathy 3 0 trials
-
Experimental gene therapy for rare muscle disease shows early promise but study halted
Disease control Stopped earlyThis study tested a gene therapy called SRP-9003 for people with limb-girdle muscular dystrophy type 2E (LGMD2E), a rare genetic disease that causes muscle weakness. The treatment aimed to deliver a working gene to muscle cells to help them produce a missing protein. Only 6 peopl…
Phase 1/2 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental gene therapy for rare muscle disease tested in just 2 people
Disease control Stopped earlyThis was a very early (Phase 1) study testing a gene therapy called SRP-6004 for people with limb girdle muscular dystrophy type 2B/R2, a rare muscle-weakening disease. The goal was to see if a single IV infusion of the therapy is safe and can help the body produce a missing prot…
Phase 1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:20 UTC
-
Experimental gene therapy tested for rare muscular dystrophy
Disease control Stopped earlyThis early-stage trial tested a gene therapy called SRP-9004 in just 4 people with limb girdle muscular dystrophy type 2D/R3, a rare muscle-weakening disease. The main goal was to check safety, not effectiveness. The study was terminated early, so results are limited.
Phase 1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:47 UTC